Collaborations & Alliances, Trials & Filings

GSK, Theravance COPD Treatment Approved

Approval triggers $30 million payment from Theravance, with another $30 mil. due to GSK at launch

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GlaxoSmithKline and Theravance have received approval from the FDA to market Anoro Ellipta as a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Anoro Ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthma. Anoro Ellipta (umeclidinium and vil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters